<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04927468</url>
  </required_header>
  <id_info>
    <org_study_id>yanghs20210607</org_study_id>
    <nct_id>NCT04927468</nct_id>
  </id_info>
  <brief_title>Supramaximal Rectus Recession for Strabismus in Grave's Ophthalmopathy</brief_title>
  <official_title>The Management of Large-angle Strabismus in Grave's Ophthalmopathy With Supramaximal Rectus Recession</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate supramaximal rectus recession for strabismus in&#xD;
      Grave's Ophthalmopathy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the effectiveness and complications of supramaximal rectus recession for&#xD;
      large-angle strabismus in Grave's Ophthalmopathy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative deviations</measure>
    <time_frame>6 weeks</time_frame>
    <description>Postoperative deviations in the primary position were measured in prism diopters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative deviations</measure>
    <time_frame>3 months</time_frame>
    <description>Postoperative deviations in the primary position were measured in prism diopters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative deviations</measure>
    <time_frame>6 months</time_frame>
    <description>Postoperative deviations in the primary position were measured in prism diopters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>binocular single vision</measure>
    <time_frame>6 weeks</time_frame>
    <description>measure the triple visual function including simultaneous vision, fusion range and distance stereoacuity with synoptophore.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>binocular single vision</measure>
    <time_frame>3 months</time_frame>
    <description>measure the triple visual function including simultaneous vision, fusion range and distance stereoacuity with synoptophore.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>binocular single vision</measure>
    <time_frame>6 months</time_frame>
    <description>measure the triple visual function including simultaneous vision, fusion range and distance stereoacuity with synoptophore.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stereoacuity</measure>
    <time_frame>6 weeks</time_frame>
    <description>measure near stereoacuity in downgaze position and distance stereoacuity in primary position with random-dot stereopsis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stereoacuity</measure>
    <time_frame>3 months</time_frame>
    <description>measure near stereoacuity in downgaze position and distance stereoacuity in primary position with random-dot stereopsis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stereoacuity</measure>
    <time_frame>6 months</time_frame>
    <description>measure near stereoacuity in downgaze position and distance stereoacuity in primary position with random-dot stereopsis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ocular motility</measure>
    <time_frame>6 weeks</time_frame>
    <description>evaluate the ocular motility with fixed visual field examination ,scaled from -4 to +4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ocular motility</measure>
    <time_frame>3 months</time_frame>
    <description>evaluate the ocular motility with fixed visual field examination,scaled from -4 to +4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ocular motility</measure>
    <time_frame>6 months</time_frame>
    <description>evaluate the ocular motility with fixed visual field examination,scaled from -4 to +4</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Strabismus, Mechanical</condition>
  <condition>Graves Ophthalmopathy</condition>
  <arm_group>
    <arm_group_label>supramaximal rectus recession</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>supramaximal rectus recession to treat large-angle restricted strabismus in thyroid associated ophthalmopathy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>normal rectus recession</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>normal rectus recession to treat large-angle restricted strabismus in thyroid associated ophthalmopathy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>supramaximal rectus recession</intervention_name>
    <description>inferior rectus recession is 10mm，medial rectus recession is 9mm,superior rectus recession is 14mm for large-angle strabismus</description>
    <arm_group_label>supramaximal rectus recession</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>normal rectus recession</intervention_name>
    <description>inferior rectus recession is 7mm，medial rectus recession is 7mm,superior rectus recession is 7mm for large-angle strabismus</description>
    <arm_group_label>normal rectus recession</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of Grave's ophthalmopathy&#xD;
&#xD;
          -  angle of deviation more than 20°&#xD;
&#xD;
          -  clinically and biochemically euthyroid for at least 3 months;&#xD;
&#xD;
          -  a stable orthoptic examination for at least 3 months, for example no greater than five&#xD;
             prism dioptre change in primary position and no greater than an 8° change in duction&#xD;
&#xD;
          -  monocular and mainly single extraocular muscle restricted motility&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with suppression, previously diagnosed and/or treated strabismus not related&#xD;
             to the thyroid&#xD;
&#xD;
          -  best-corrected visual acuity (BCVA) less than 0.2 in one or both eyes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yang Huasheng</last_name>
    <phone>+00862087331539</phone>
    <email>yanghs64@163.com</email>
  </overall_contact>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 8, 2021</study_first_submitted>
  <study_first_submitted_qc>June 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2021</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Huasheng Yang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Strabismus</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Graves Ophthalmopathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

